{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:35:15Z","timestamp":1777300515929,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The CAPRISA 018 Phase I trial evaluated the safety, tolerability and pharmacokinetics of a 110\u00a0mg tenofovir alafenamide (TAF) implant for HIV prevention in South African women. This follow\u2010up cohort study, CAPRISA 097, assessed the long\u2010term resolution of implant site reactions (ISRs) after implant removal and explored user acceptability and implant attribute preferences to inform the development of next\u2010generation pre\u2010exposure prophylaxis (PrEP) implants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women previously enrolled in CAPRISA 018 were recruited and followed quarterly for 12 months between 13 October 2022 and 27 October 2023. ISR prevalence, severity and resolution were evaluated at each visit. Implant acceptability, implant attribute preferences and PrEP preferences were assessed at enrolment and at month 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 36 eligible participants, 35 were enrolled a median of 299 days after implant removal (IQR: 243\u2013490). At enrolment, all 35 participants (100%) had ongoing mild (Grade 1) scarring, with additional findings of hyperpigmentation (14%), induration (6%) and hypopigmentation (3%). By study exit, scarring persisted in all participants (median duration: 623 days; IQR: 579\u2013819), while hyperpigmentation and induration remained in two and one participant, respectively. Acceptability ratings for implant visibility were similar at enrolment and month 12 (77.1%\u00a0vs. 75.0%), as were ratings for pain (68.6%\u00a0vs. 78.1%). Side effects due to ISRs received the highest \u201cvery unacceptable\u201d ratings, in 37.1% of participants at enrolment and 21.9% at study exit. Scarring was considered acceptable by 65.7% of participants at enrolment, increasing to 78.1% at exit. Perceived partner interest in the various PrEP products aligned with participant interest. A palpable 12\u2010month implant was acceptable to most participants, whereas increased length, width or stiffness reduced the likelihood of use. Preferred PrEP options were a 12\u2010monthly implant (38.2% at enrolment vs. 50.0% at month 12), a 6\u2010monthly injection (29.0%\u00a0vs. 37.5%) and daily oral PrEP tablets (12.0%\u00a0vs. 3.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mild but persistent scarring was observed following TAF implant removal, with limited cases of hyperpigmentation and induration. Despite these local side effects, a 12\u2010monthly implant remained the most preferred PrEP option among women previously enrolled in the TAF implant trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70107","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:01:48Z","timestamp":1776322908000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Tenofovir Alafenamide Sub\u2010Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-5128","authenticated-orcid":false,"given":"Tanuja N.","family":"Gengiah","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Lewis","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishana","family":"Harkoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nqobile","family":"Myeni","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-348X","authenticated-orcid":false,"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S. Abdool","family":"Karim","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"},{"name":"Department of Epidemiology Columbia University Mailman School of Public Health  New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quarraisha Abdool","family":"Karim","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa University of KwaZulu\u2010Natal  Durban South Africa"},{"name":"Department of Epidemiology Columbia University Mailman School of Public Health  New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"The Urgency of Now: AIDS at a Crossroads","author":"UNAIDS","year":"2024"},{"key":"e_1_2_11_3_1","volume-title":"HIV and AIDS Estimates Country Facts Sheet","author":"UNAIDS","year":"2023"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001316"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(20)30304\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)00538\u20104"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)00056\u20102"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4506"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai9383"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0464"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25957"},{"key":"e_1_2_11_18_1","unstructured":"InternationalPartnership for Microbicides South Africa Approves Dapivirine Vaginal Ring for Use by Women(2022) https:\/\/www.eatg.org\/hiv-news\/south-africa-approves-dapivirine-vaginal-ring-for-use-by-women\/."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656\u201015"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201011020\u20102"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01893\u201019"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2021.0028"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(25)00079\u20107"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26426"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010052880"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001479\u20103"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003135"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1538"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060548"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010020\u201002808\u20102"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010023\u201004202\u20100"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010022\u201003658\u2010w"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905\u2010023\u201002181\u2010x"},{"issue":"3","key":"e_1_2_11_34_1","article-title":"The Influence of HIV\u2010Related Stigma on PrEP Disclosure and Adherence Among Adolescent Girls and Young Women in HPTN 082: A Qualitative Study","volume":"23","author":"Velloza J.","year":"2020","journal-title":"African Journal of Reproduction and Gynaecological Endoscopy"},{"issue":"2","key":"e_1_2_11_35_1","first-page":"84","article-title":"The Intersection of Intimate Partner Violence and HIV: Detection, Disclosure, Discussion, and Implications for Treatment Adherence","volume":"27","author":"Sullivan T. P.","year":"2019","journal-title":"Topics in Antiviral Medicine"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:38:17Z","timestamp":1777297097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jia2.70107"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70107","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70107"}}